Mylan taps Pfizer to inject buzz into Japan EpiPen sales
This article was originally published in Scrip
Executive Summary
Mylan is to transfer the Japanese sales and marketing rights to the newest version of its EpiPen emergency epinephrine injection product to Pfizer, building on the latter company's extensive commercial network in the country.